Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 120

1.
2.

Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus.

Puhlmann J, Puehler F, Mumberg D, Boukamp P, Beier R.

Oncogene. 2010 Apr 15;29(15):2205-16. doi: 10.1038/onc.2009.507. Epub 2010 Jan 25.

PMID:
20101224
3.

Newcastle disease virus-induced cytopathic effect in infected cells is caused by apoptosis.

Ravindra PV, Tiwari AK, Ratta B, Chaturvedi U, Palia SK, Chauhan RS.

Virus Res. 2009 Apr;141(1):13-20. doi: 10.1016/j.virusres.2008.12.008. Epub 2009 Jan 17.

PMID:
19152817
4.

Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma.

Zulkifli MM, Ibrahim R, Ali AM, Aini I, Jaafar H, Hilda SS, Alitheen NB, Abdullah JM.

Neurol Res. 2009 Feb;31(1):3-10. doi: 10.1179/174313208X325218. Epub 2008 Oct 18.

PMID:
18937888
5.

Newcastle disease virus pathotypes.

Alexander DJ, Allan WH.

Avian Pathol. 1974 Oct;3(4):269-78.

PMID:
18777282
6.

Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial.

Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM.

Cancer Immunol Immunother. 2009 Jan;58(1):61-9. doi: 10.1007/s00262-008-0526-1. Epub 2008 May 17.

PMID:
18488223
7.

Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus.

Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, Martínez-Sobrido L, Woo SL, García-Sastre A.

Cancer Res. 2007 Sep 1;67(17):8285-92.

8.

Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus.

Lorence RM, Roberts MS, O'Neil JD, Groene WS, Miller JA, Mueller SN, Bamat MK.

Curr Cancer Drug Targets. 2007 Mar;7(2):157-67. Review.

PMID:
17346107
9.
10.

p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines.

Fábián Z, Csatary CM, Szeberényi J, Csatary LK.

J Virol. 2007 Mar;81(6):2817-30. Epub 2007 Jan 10.

11.

Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid.

Wagner S, Csatary CM, Gosztonyi G, Koch HC, Hartmann C, Peters O, Hernáiz-Driever P, Théallier-Janko A, Zintl F, Längler A, Wolff JE, Csatary LK.

APMIS. 2006 Oct;114(10):731-43.

PMID:
17004977
12.
13.

A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization.

Laurie SA, Bell JC, Atkins HL, Roach J, Bamat MK, O'Neil JD, Roberts MS, Groene WS, Lorence RM.

Clin Cancer Res. 2006 Apr 15;12(8):2555-62.

14.

Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence.

Fiola C, Peeters B, Fournier P, Arnold A, Bucur M, Schirrmacher V.

Int J Cancer. 2006 Jul 15;119(2):328-38.

15.

Virus-based therapies for colon cancer.

Morse MA.

Expert Opin Biol Ther. 2005 Dec;5(12):1627-33. Review.

PMID:
16318426
17.

Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme.

Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS, Galun E, Siegal T.

Mol Ther. 2006 Jan;13(1):221-8. Epub 2005 Oct 28.

18.
20.

T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.

Haas C, Lulei M, Fournier P, Arnold A, Schirrmacher V.

Vaccine. 2005 Mar 31;23(19):2439-53.

PMID:
15752830

Supplemental Content

Support Center